A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer · Extragonadal Yolk Sac Tumors · Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 630 (planned)
- Started
- Jul 23, 2024
- Main results expected
- Mar 31, 2027
- Fully finished
- Oct 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Up to approximately 2 years
Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033
Measured over: Up to approximately 2 years
Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033
Measured over: Up to approximately 2 years
Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06427941 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC